The following side effects were more frequently reported with the use of ProQuad:
Other side effects have been reported with the administration of at least one of the following vaccines: ProQuad, previous formulations of monovalent and combined measles, mumps, and rubella vaccines manufactured byMerckSharp & Dohme LLC, Rahway, NJ 07065, USA.(hereinafter MSD), or Varicella Live Virus Vaccine (Oka/Merck). These adverse events include:
Your doctor has a more comprehensive list of side effects for ProQuad and for the components of ProQuad (measles, mumps, and rubella vaccines manufactured by MSD and Varicella Live Virus Vaccine (Oka/Merck)).
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through thenational notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this vaccine out of sight and reach of children.
Do not use this vaccine after the expiration date that appears on the outer packaging after CAD. The expiration date is the last day of the month indicated.
Store and transport refrigerated (between 2°C and 8°C).
Do not freeze.
Store the vial in the outer packaging to protect it from light.
Medicines should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of ProQuad
After reconstitution, one dose (approximately 0.5 ml) contains:
The active ingredients are:
Measles virus 1 strain Enders’ Edmonston (live, attenuated) No less than 3.00 log 10 TCID 50*
Mumps virus 1 strain Jeryl Lynn (Level B) (live, attenuated) No less than 4.30 log 10 TCID 50*
Rubella virus 2 strain Wistar RA 27/3 (live, attenuated) No less than 3.00 log 10 TCID 50*
Varicella virus 3 strain Oka/Merck (live, attenuated) No less than 3.99 log 10 UFP**
* Dose that infects 50% of the histocultures
** Plaque-forming units
(1) Produced in chicken embryo cells.
(2) Produced in human diploid lung fibroblasts (WI-38).
(3) Produced in human diploid cells (MRC-5).
The other components are:
Sugar
Sucrose, hydrolyzed gelatin, urea, sodium chloride, sorbitol (E-420), monosodium glutamate, sodium phosphate, sodium bicarbonate, potassium phosphate, potassium chloride, Hanks' balanced salt solution, MEM, neomycin, phenol red, hydrochloric acid (HCl), and sodium hydroxide (NaOH).
Vehicle
Water for injection.
Appearance of the product and contents of the container
The vaccine is a powder for suspension for injection contained in a single-dose vial, which must be mixed with the vehicle supplied with the powder vial.
The powder is a compact crystalline mass of white to pale yellow color, and the vehicle is a clear, colorless liquid.
ProQuad is available in containers of 1, 10, and 20. Only some container sizes may be marketed.
Marketing authorization holder and manufacturer
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Netherlands
For more information about this medicinal product, please contact the local representative of the marketing authorization holder.
België/Belgique/Belgien MSD Belgium Tel/Tel: +32(0)27766211 | Lietuva UAB Merck Sharp & Dohme | |
Luxembourg/Luxemburg MSD Belgium Tél/Tel: +32 (0)27766211 | ||
Ceská republika Merck Sharp & Dohme s.r.o. | Magyarország MSD Pharma Hungary Kft. | |
Danmark MSD Danmark ApS Tlf.: + 45 4482 4000 | Malta Merck Sharp & Dohme Cyprus Limited. | |
Deutschland MSD Sharp & Dohme GmbH Tel.:+49 (0) 89 20 300 4500 | Nederland Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) | |
Eesti Merck Sharp & Dohme OÜ Tel: +372614 4200 | Norge MSD (Norge) AS Tlf: +47 32 20 73 00 | |
Ελλ?δα MSDΑ.Φ.Ε.Ε. Τηλ: +30 210 98 97 300 dpoc_greece@merck.com | Österreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 dpoc_austria@merck.com | |
España Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 | Polska MSD Polska Sp. z o.o. | |
France MSD France | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 | |
Hrvatska Merck Sharp & Dohme d.o.o. | România Merck Sharp & Dohme Romania S.R.L Tel: + 4021 529 29 00 | |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 | Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. | |
Ísland Vistor hf. Sími: + 354 535 7000 | Slovenská republika Merck Sharp & Dohme, s. r. o. | |
Italia MSD Italia S.r.l. Tel:800 23 99 89 (+39 06 361911) | Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0)9 804 650 | |
Κ?προς Merck Sharp & Dohme Cyprus Limited cyprus_info@merck.com | Sverige Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 | |
Latvija SIA Merck Sharp & Dohme Latvija | United Kingdom (Northern Ireland) Merck Sharp & DohmeIreland (Human Health) Limited Tel: +353 (0)1 2998700 |
Last update of this leaflet:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency:https://www.ema.europa.eu.
This information is intended solely for healthcare professionals:
Before mixing with the vehicle, the vaccine powder is a compact crystalline mass of white to pale yellow color. The vehicle is a clear, colorless liquid. When fully reconstituted, the vaccine is a pale yellow to pinkish liquid.
For the reconstitution of the vaccine, only the vehicle supplied should be used, as it lacks preservatives or other antiviral substances capable of inactivating the vaccine.
It is essential to use a new, sterile syringe and needle for each individual to prevent the transmission of infectious agents from one person to another.
A separate needle should be used for reconstitution and another for injection.
ProQuad should not be mixed in the same syringe with other vaccines.
Instructions for reconstitution
To place the needle, firmly attach it to the end of the syringe and secure it with a twist.
Inject the entire contents of the vehicle from the syringe into the vial containing the powder. Gently agitate to mix thoroughly.
The reconstituted vaccine should be visually inspected for any foreign particles and/or variation in physical appearance before administration. If any of the above are observed, discard the vaccine.
It is recommended that the vaccine be administered immediately after reconstitution, to minimize loss of potency. Discard the reconstituted vaccine if not used within 30 minutes.
Do not freeze the reconstituted vaccine.
Extract the entire contents of the reconstituted vaccine from the vial into a syringe, change the needle, and inject the entire contents subcutaneously or intramuscularly.
Unused products or waste materials should be disposed of in accordance with local requirements.
See also Section 3 How to use ProQuad
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.